27 November, 2017
  • The Navitas Life Sciences’ traceREADY platform provides next generation mobility for extended ERP transactions and other Enterprise Applications. traceREADY operates on:
  • traceREADY helps organizations automate manufacturing /warehousing operations to implement SOPs, avoid major errors like product mix-up, collect data for serialization and create an EPCIS repository
  • The advent of Serialization and DSCSA compliance begins in November, 2017. Products and materials that are not compliant will be stopped in process.
  • Navitas Life Sciences’ traceREADY platform offers a quick implementation phase (16–24 Weeks) complimented by an unique process assessment exercise that insures quick user adoption and minimal change management
  • Navitas Life Sciences can save organizations up to 30-40% on implementation costs when compared to competitive solutions

Read more...

traceready value proposition

09
Jun2017

Life Sciences expert Navitas augments end-to-end capabilities

Navitas, a technology-led Life Sciences services provider across Clinical, Regulatory and Safety, announced that it would be...

05
Oct2016

Navitas Life Sciences at DIA's 10th Annual Forum for...

Navitas Principal Jeffrey Ho will present "Efficient content management for the compilation and management of the...

16
Oct2015

Navitas Life Sciences Introduces Innovative Regulatory Process Outsourcing Model

The workload for regulatory functions of pharmaceutical companies has continued to increase in recent years ...

09
Jun2017

Life Sciences expert Navitas augments end-to-end capabilities

Navitas, a technology-led Life Sciences services provider across Clinical, Regulatory and Safety, announced that it would be...

05
Oct2016

Navitas Life Sciences at DIA's 10th Annual Forum for...

Navitas Principal Jeffrey Ho will present "Efficient content management for the compilation and management of the...

16
Oct2015

Navitas Life Sciences Introduces Innovative Regulatory Process Outsourcing Model

The workload for regulatory functions of pharmaceutical companies has continued to increase in recent years ...